Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer
- PMID: 37633202
- DOI: 10.1016/j.ejmech.2023.115730
Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer
Abstract
The development of drugs for the treatment of advanced prostate cancer (PCA) remains a challenging task. In this study we have designed, synthesized and tested twenty-nine novel HDAC inhibitors based on three different zinc binding groups (trifluoromethyloxadiazole, hydroxamic acid, and 2-mercaptoacetamide). These warheads were conveniently tethered to variously substituted phenyl linkers and decorated with differently substituted pyrrolo-pyrimidine and purine cap groups. Remarkably, most of the compounds showed nanomolar inhibitory activity against HDAC6. To provide structural insights into the Structure-Activity Relationships (SAR) of the investigated compounds, docking of representative inhibitors and molecular dynamics of HDAC6-inhibitor complexes were performed. Compounds of the trifluoromethyloxadiazole and hydroxamic acid series exhibited promising anti-proliferative activities, HDAC6 _targeting in PCA cells, and in vitro tumor selectivity. Representative compounds of the two series were tested for solubility, cell permeability and metabolic stability, demonstrating favorable in vitro drug-like properties. The more interesting compounds were subjected to migration assays, which revealed that compound 13 and, to a lesser extent, compound 15 inhibited the invasive behaviour of androgen-sensitive and -insensitive advanced prostate cancer cells. Compound 13 was profiled against all HDACs and found to inhibit all members of class II HDACs (except for HDAC10) and to be selective with respect to class I and class IV HDACs. Overall, compound 13 combines potent inhibitory activity and class II selectivity with favorable drug-like properties, an excellent anti-proliferative activity and marked anti-migration properties on PCA cells, making it an excellent lead candidate for further optimization.
Keywords: Drug design; HDAC inhibitors; HDAC6; Prostate cancer; Trifluoromethyloxadiazole (TFMO).
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.Eur J Med Chem. 2022 Jan 5;227:113893. doi: 10.1016/j.ejmech.2021.113893. Epub 2021 Oct 2. Eur J Med Chem. 2022. PMID: 34656899
-
Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors.J Enzyme Inhib Med Chem. 2022 Dec;37(1):1918-1927. doi: 10.1080/14756366.2022.2097446. J Enzyme Inhib Med Chem. 2022. PMID: 35833370 Free PMC article.
-
Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.Bioorg Med Chem. 2014 Nov 1;22(21):6146-55. doi: 10.1016/j.bmc.2014.08.030. Epub 2014 Sep 4. Bioorg Med Chem. 2014. PMID: 25261927
-
Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.Eur J Med Chem. 2017 Jul 28;135:174-195. doi: 10.1016/j.ejmech.2017.04.013. Epub 2017 Apr 10. Eur J Med Chem. 2017. PMID: 28453994 Review.
-
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.Eur J Med Chem. 2021 Jan 1;209:112887. doi: 10.1016/j.ejmech.2020.112887. Epub 2020 Sep 29. Eur J Med Chem. 2021. PMID: 33035922 Free PMC article. Review.
Cited by
-
Searching for Novel HDAC6/Hsp90 Dual Inhibitors with Anti-Prostate Cancer Activity: In Silico Screening and In Vitro Evaluation.Pharmaceuticals (Basel). 2024 Aug 15;17(8):1072. doi: 10.3390/ph17081072. Pharmaceuticals (Basel). 2024. PMID: 39204176 Free PMC article.
-
Single-cell landscape and spatial transcriptomic analysis reveals macrophage infiltration and glycolytic metabolism in kidney renal clear cell carcinoma.Aging (Albany NY). 2023 Oct 16;15(20):11298-11312. doi: 10.18632/aging.205128. Epub 2023 Oct 16. Aging (Albany NY). 2023. PMID: 37847178 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous